|By PR Newswire||
|March 17, 2014 01:08 PM EDT||
NEW YORK, March 17, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The 3D printing industry has come a long way over the last many years; the technology has the potential of revolutionising the way things occur currently. Many industries have already benefitted from multiple advancements in this field, resulting in improved and more efficient processes worldwide. A quick look at www.3dprintingchannel.com suggests that 3D printing has multi-faceted dimensions; the technology has recently been used in varied industries such as automotive, medical, business, industrial equipments, education, architecture, and consumer products. There is a widespread optimism that it is likely to gain prominence in the coming years and have a far reaching impact on our daily lives.
Within healthcare, 3D printed prosthetics and implants have already been in the market for some years. Layerwise from Belgium and Xilloc from Netherlands are the major companies dealing with 3D printed medical and dental implants. Xilloc was in the news recently for creating the first customized 3D-printed lower jaw for an 83-year old patient with a serious jaw infection. Another company, Oxford Performance Materials, from USA, received FDA approval for a 3D printed implant that replaced 75% of a man's skull.
Specifically, 3D bioprinting is gradually emerging as an area which is garnering attention from a lot of academicians. Some of these researchers have also recently opened start-up firms with the aim of commercialising the technology over the next decade or so.
SCOPE OF THE REPORT
The '3D Bioprinting, 2014 - 2030' report provides an extensive study of the emerging market of 3D bioprinting, specifically focusing on commercial bioprinters and those under development, their applications and the likely future evolution. It is widely anticipated that the 3D bioprinting market has tremendous potential: it requires hardware (bioprinters), software (CAD), biocompatible materials (bio-ink and bio-paper), each of which has the capability to grow into separate niche industries. The report covers various aspects such as technological progress, product pipeline, industry and academic research programs and regulatory concerns to assess new evolving opportunities.
One of the key objectives of this report is to understand the current and future state of the bioprinters and products derived thereof. This is done by analysing the following:
- Commercial 3D Bioprinters currently available in the market
- Innovations of academic groups across various research institutes across the globe
- Competing technologies with similar applications in the healthcare industry
- Size of target consumer segments
- The widening supply-demand gap, specifically for organ transplants.
The base year for the report is 2014. The report provides short-mid term and long term market forecasts for the period 2014 - 2024 and 2024 - 2030, respectively. We have discussed, in detail, key drivers behind the likely growth of 3D bioprinting market. The research, analysis and insights presented in this report include the sales potential of various 3D bioprinted products based on the current expected market launch timelines, their adoption rates and the estimated end-use price points. The figures mentioned in this report are in USD, unless otherwise specified.
1. As of today, the industry is primarily focused on research and development; apart from the limited number of industry initiatives, academic groups worldwide are involved in exemplary research in the field of 3D bioprinting.
2. A number of start-ups have recently sprung up to develop products based on bioprinting; some of these are spin outs from university research. Examples include TeViDo BioDevices (focused on printing breast tissue), Aspect Biosystems (focused on printing tissue models for toxicity testing) and SkinPrint (focused on developing human skin).
3. The market currently has 14 industry sponsored bioprinters, focused on a variety of commercial applications. The widening supply-demand gap for organ transplants is a huge unmet need; the eventual goal of researchers is to be able to produce bioprinted organs for organ transplants.
4. As the development progresses, the next generation of bioprinters are likely to offer additional features (e.g. multiple arms) and are likely to be relatively more affordable driving wider adoption.
5. We believe that the market will progress gradually over the coming decade; however, the focus is likely to shift from research to commercialisation by the second half of next decade. At this stage, applications such as drug testing and tissue engineering (skin and cartilage) are likely to be popular.
6. By 2030, we predict 3D bioprinting to be a multi-billion dollar industry; early success of bioprinted organ transplants is likely to provide additional boost in subsequent years.
Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include
1. Annual reports
2. Investor presentations
3. SEC filings
4. Industry databases
5. News releases from company websites
6. Government policy documents
7. Other analysts' opinion reports
While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on where the 3D bioprinting market is headed in the mid-long term.
Chapter 3 provides a general introduction to 3D bioprinting. We have discussed, in detail, the origins of 3D printing and recent developments which have shaped the industry so far. The chapter also elaborates on the 'bioprinting' process, current and future applications, and the challenges which have to be overcome before wider adoption of the technology.
Chapter 4 provides an overview of the 3D bioprinting market with respect to the available bioprinting technologies and companies active in the field. The analysis also extends to regional evolution and the key drivers which will determine the future growth.
Chapter 5 offers a comprehensive review of the major bioprinters which have been made available by leading companies in the market. We present profiles of eight technologies with information about their origin, printing process, applications, principal features, current status and expected future evolution.
Chapter 6 reviews, in detail, the major bioprinters offered by academic institutions dominant in the field. We present profiles of five leading technologies with information about their origin, printing process, applications, principal features, current status and likely future evolution.
Chapter 7 analyses the current and future state of the worldwide market of 3D bioprinting. The chapter includes our estimates of the value of the market for end-user applications till 2030. Given the current niche nature of the technology, we have done a multi-variate sensitivity analysis to present three different tracks of industry's evolution.
Chapter 8 provides our analysis of the strengths, weaknesses, opportunities and threats in the 3D bioprinting market, capturing the key elements likely to influence future growth.
Chapter 9 provides case studies on Organovo and regenHU, two companies active in the 3D bioprinting arena. The case studies include detailed analysis of financial performance (where available), marketed / pipeline bioprinting products, recent developments, and future focus areas.
Chapter 10 is a collection of six transcripts based on our discussion with some of the leading players in the industry. The companies / academic institutes interviewed include n3D Biosciences, regenHU, Sciperio / nScrypt, MicroFab Technologies, Digilab and TeVido BioDevices.
Chapter 11 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.
Chapters 12 and 13 are appendices, which provide the list of companies and tabulated data for all the figures presented in the report.
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3.1. Chapter Overview
3.2. 3D Printing Technology
3.2.1. What is 3D Printing?
3.2.2. Historical Evolution
3.3. 3D Bioprinting Process And Components
3.4. Entry of 3D Printing into Medical Arena
3.4.1. Key Players
3.4.2. 3D Bioprinting Applications
126.96.36.199. Toxicity Screening / Drug Testing
188.8.131.52. Tissue Engineering
184.108.40.206. Organ Replacement via Organ Printing
220.127.116.11. High Initial Cost
18.104.22.168. Regulatory Issues
22.214.171.124. Functional Aspects Not Yet Fully Tested
126.96.36.199. Limited Capability for Complicated Tissues and Organs
188.8.131.52. Hurts Moral and Religious Beliefs
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Limited Professional Bioprinters in Market
4.3. Prices are Largely Prohibitive
4.4. The US is Leading the Efforts; Developing Countries Have Begun to Contribute
4.5. Start-ups Emerging as Key Players
4.6. Bioprinting: Finding its Root in University Research
4.7. Development of Multi-Arm Bioprinters: The Next Generation of Bioprinters
5. PROFILES: COMMERCIAL BIOPRTINERS AND PRODUCTS
5.1. Chapter Overview
5.2. Novogen MMX - Organovo
5.2.1. Overview and Origin
5.2.2. Development of NovoGen MMX
5.2.4. Awards and Accomplishments
5.2.5. The Bioprinting Process
5.2.7. Key Features
184.108.40.206. Microtissues for Drug Discovery and Research
220.127.116.11. Longer Term, Organ Printing for Transplantation
18.104.22.168. Regenerative Medicine
5.2.9. Partnerships and Agreements
22.214.171.124. United Therapeutics
126.96.36.199. Methuselah Foundation
5.3. 3D-Bioplotter - EnvisionTEC
5.3.1. Overview and Origin
5.3.2. The Bioprinting Process
188.8.131.52. Provides 'smart' scaffolds for tissue engineering
184.108.40.206. Cell and Tissue Printing
220.127.116.11. 3D-Anatomical Models for Study
5.3.4. Key Features
5.3.5. Academic Institutions using 3D Bioplotter
5.4. BioFactory - regenHU
5.4.1. Overview and Origin
5.4.3. Research Collaborations
18.104.22.168. ETH, Zurich
5.5. BioAssembly Tool - Sciperio / nScrypt
5.5.1. Overview and Origin
5.5.2. The Bioprinting Process
5.5.3. Key Features
22.214.171.124. Cardiovascular Innovation Institute
5.5.5. Awards / Accomplishments
126.96.36.199. Bioficial Heart
188.8.131.52. Other Tissues
5.6. Microfluidic-based Bioprinting Platform - Aspect Biosystems
5.6.1. Overview and Origin
5.6.2. The Bioprinting Process
5.6.3. Key Features
5.6.4. Building Tissue Constructs For Drug Discovery
184.108.40.206. MEMSCAP Design Award 2013
220.127.116.11. Federal Support Through IRAP
5.7. Modified Ink-jet Bioprinter - TeVido BioDevices
5.7.1. Overview and Origin
5.7.3. The Bioprinting Process
5.7.4. Key Features
18.104.22.168. Breast Reconstruction
22.214.171.124. Drug Testing
126.96.36.199. Other Reconstructive Tissue Products
188.8.131.52. Treatment for Chronic Wounds
184.108.40.206. Breast Augmentation
5.8. Other Initiatives
5.8.2. 3DDiscovery - regenHU
220.127.116.11. Key Features
18.104.22.168. Research Collaborations
6. PRODUCT PROFILES: ACADEMIC INSTITUTES
6.1. Chapter Overview
6.2. BioPen - University of Wollongong / St. Vincent Hospital
6.2.1. Overview and Origin
6.2.2. The Bioprinting Process
6.2.3. Advantages of BioPen
6.3. Modified Ink-jet Bioprinter for Skin Cells - Wake Forest Institute for Regenerative Medicine / Armed Forces Institute For Regenerative Medicine
6.3.2. The Bioprinting Process
6.3.3. Key Features
6.3.4. Bioprinting Human Skin
6.3.5. Awards / Accomplishments
6.4. Modified Ink-jet Printer for Tissues and Organs - Wake Forest Institute for Regenerative Medicine
6.4.2. The Bioprinting Process
22.214.171.124. Tissue Patches
126.96.36.199. Potential to Print Organs
188.8.131.52. Organs on a Chip
6.5. Regenovo - Hangzhou Dianzi University, China
6.5.2. The Bioprinting Process
6.5.3. Key Features
6.6. Valve Based Technology - Heriot-Watt University / Roslin Cellab
6.6.1. Overview and Origin
6.6.2. The Bioprinting Process
6.6.3. Key Features
184.108.40.206. Drug Testing for Pharmaceutical Research
220.127.116.11. Tissue Regeneration
18.104.22.168. Custom-built Replacement Organs
6.6.5. Awards / Accomplishments
22.214.171.124. Reinnervate Ltd.
7. MARKET FORECAST
7.1. Chapter Overview
7.2. Forecast Methodology
7.3. The 3D Bioprinting Market, 2014 - 2030
7.3.2. Market Forecast: Drug Testing (Base Scenario)
7.3.3. Market Forecast: 3D Bioprinted Skin (Base Scenario)
7.3.4. Market Forecast: 3D Printed Cartilage Replacement (Base Scenario)
7.3.5. Market Forecast: 3D Printed Organ Transplants (Base Scenario)
7.3.6. Overall Market Forecast (Base Scenario)
8. SWOT ANALYSIS
8.1. Chapter Overview
8.2.1. Faster Drug Discovery
8.2.2. A Quality Alternative to Animal Testing
8.3.1. High Initial Investment
8.3.2. Integration of Vascular Network
8.4.1. Low Entry Barriers
8.4.2. Growing Wait List for Organ Transplants – A Huge Unmet Need
8.5.1. Regulatory Barrier
8.5.2. Commercial 3D Cell Culture Systems
9. CASE STUDIES
9.1. Organovo Holdings, Inc.
10. INTERVIEW TRANSCRIPTS
10.1. Interview 1: n3D Biosciences (Glauco R. Souza, President and CSO & Hubert Tseng, Senior Research Scientist)
10.2. Interview 2: regenHU (Marc Thurner, CEO)
10.3. Interview 3: Sciperio / nScrypt (Kenneth Church, President and CEO & Xudong Chen, Vice President)
10.4. Interview 4: MicroFab Technologies (Anonymous)
10.5. Interview 5: Digilab (Dr. Igor Zlatkin, Application Scientist & Chirantan Kanani, Technology and Product Development)
10.6. Interview 6: TeVido BioDevices (Laura Bosworth, CEO and Co-Founder)
11.1. 3D Bioprinting has Emerged Well Since Inception
11.2. Commercial Bioprinters Are Limited; Research Labs and Spin-outs from Academia Continue to Progress
11.3. Organ Supply - Demand Gap: A Major Growth Driver
11.4. Overall a Multi-billion Dollar Opportunity by 2030
11.5. Challenges Exist Before Bioprinting Becomes Mainstream
12. APPENDIX 1: LIST OF COMPANIES AND ORGANISATIONS
13. APPENDIX 2: TABLES
LIST OF FIGURES
Figure 3.1 The 'Bioprinting' Process
Figure 4.1 Industry Sponsored Bioprinters: Regional Distribution
Figure 4.2 Industry Sponsored Bioprinters: Distribution by Status
Figure 4.3 University Sponsored Bioprinters: Regional Distribution
Figure 5.1 Bioplotter: Printing Process
Figure 7.1 Drug Testing Market, Short-Mid Term, Base Scenario (USD MM)
Figure 7.2 Drug Testing Market, Long Term, Base Scenario (USD MM)
Figure 7.3 3D Bioprinted Skin Market, Short-Mid Term, Base Scenario (USD MM)
Figure 7.4 3D Bioprinted Skin Market, Long Term, Base Scenario (USD MM)
Figure 7.5 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Base Scenario (USD MM)
Figure 7.6 3D Bioprinted Cartilage Replacement Market, Long Term, Base Scenario (USD MM)
Figure 7.7 3D Bioprinted Organ Transplants, Long Term, Base Scenario (USD MM)
Figure 7.8 Overall 3D Bioprinted Products Market, Short-Mid Term, Base Scenario (USD MM)
Figure 7.9 Overall 3D Bioprinted Products Market, Long Term, Base Scenario (USD MM)
Figure 10.1 Process of Magnetic Bioprinting
Figure 10.2 3D Cell Bioprinting: Magnetically Beyond Rings and Dots
Figure 10.3 n3D vs. Organovo 3D Bioprinting
Figure 11.1 3D Bioprinting Market, 2018, 2024, 2030 (USD MM)
Figure 11.2 3D Bioprinting: The Driving Forces
LIST OF TABLES
Table 3.1 RepRap Project: 3D Printing Machines
Table 3.2 Inputs for 3D Bioprinting
Table 4.1 List of Bioprinters: Industry Sponsored
Table 4.2 Companies Developing Bioprinted Products for Commercial Purposes
Table 4.3 Universities Working in the Area of Bioprinting
Table 5.1 NovoGen MMX: Patent Portfolio
Table 5.2 Materials Used for Scaffolds
Table 5.3 SmartPump - Models and Features
Table 7.1: 3D Bioprinted Applications: Launch Timeline
Table 7.2 3D Bioprinted Skin: Competitive Landscape
Table 8.1 SWOT Analysis
Table 8.2 3D Cell Culture Systems
Table 9.1 3D Liver Assays - Launch Timeline
Table 9.2 Organovo's Plans for Revenue Generation from 3D Bioprinted Liver
Table 9.3 Organovo Revenues – 2011, 2012, and Q1 2013
Table 9.4 regenHU: 3D Bioprinting Product Portfolio
Table 13.1 Industry Sponsored Bioprinters: Regional Distribution
Table 13.2 Industry Sponsored Bioprinters: Distribution by Status
Table 13.3 University Sponsored Bioprinters: Regional Distribution
Table 13.4 Drug Testing Market, Short-Mid Term, Base Scenario (USD MM)
Table 13.5 Drug Testing Market, Long Term, Base Scenario (USD MM)
Table 13.6 Drug Testing Market, Short-Mid Term, Conservative Scenario (USD MM)
Table 13.7 Drug Testing Market, Long Term, Conservative Scenario (USD MM)
Table 13.8 Drug Testing Market, Short-Mid Term, Optimistic Scenario (USD MM)
Table 13.9 Drug Testing Market, Long Term, Optimistic Scenario (USD MM)
Table 13.10 3D Bioprinted Skin Market, Short-Mid Term, Base Scenario (USD MM)
Table 13.11 3D Bioprinted Skin Market, Long Term, Base Scenario (USD MM)
Table 13.12 3D Bioprinted Skin Market, Short-Mid Term, Conservative Scenario (USD MM)
Table 13.13 3D Bioprinted Skin Market, Long Term, Conservative Scenario (USD MM)
Table 13.14 3D Bioprinted Skin Market, Short-Mid Term, Optimistic Scenario (USD MM)
Table 13.15 3D Bioprinted Skin Market, Long Term, Optimistic Scenario (USD MM)
Table 13.16 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Base Scenario (USD MM)
Table 13.17 3D Bioprinted Cartilage Replacement Market, Long Term, Base Scenario (USD MM)
Table 13.18 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Conservative Scenario (USD MM)
Table 13.19 3D Bioprinted Cartilage Replacement Market, Long Term, Conservative Scenario (USD MM)
Table 13.20 3D Bioprinted Cartilage Replacement Market, Short-Mid Term, Optimistic Scenario (USD MM)
Table 13.21 3D Bioprinted Cartilage Replacement Market, Long Term, Optimistic Scenario (USD MM)
Table 13.22 3D Bioprinted Organ Transplants, Long Term, Base Scenario (USD MM)
Table 13.23 3D Bioprinted Organ Transplants, Long Term, Conservative Scenario (USD MM)
Table 13.24 3D Bioprinted Organ Transplants, Long Term, Optimistic Scenario (USD MM)
Table 13.25 3D Bioprinted Products Market, Short-Mid Term, Base Scenario (USD MM)
Table 13.26 3D Bioprinted Products Market, Long Term, Base Scenario (USD MM)
Table 13.27 3D Bioprinted Products Market, Short-Mid Term, Conservative Scenario (USD MM)
Table 13.28 3D Bioprinted Products Market, Long Term, Conservative Scenario (USD MM)
Table 13.29 3D Bioprinted Products Market, Short-Mid Term, Optimistic Scenario (USD MM)
Table 13.30 3D Bioprinted Products Market, Long Term, Optimistic Scenario (USD MM)
The following companies have been mentioned in the report.
1. 3D Biotek
2. 3D Systems
3. Advanced Biomatrix
5. Aspect Biosystems
8. Avita Medical
9. BD Biosciences
10. Bespoke Innovations
11. Bio3D Technologies
13. CMC Microsystems
15. CP Automation
16. Cuspis LLC
17. Cyfuse Biomedical
23. Hangzhou Dianzi University, China
24. Helisys Inc.
25. Heriot-Watt University
28. InSphero AG
32. Kor Ecologic
34. MakerBot Industries
36. Methuselah Foundation
37. MicroFab Technologies
38. Modern Meadows
39. n3D Biosciences
40. Nano3D Biosciences
41. National Institute of Health
44. Objective 3D
45. Objet Geometries Ltd
46. Organovo Holdings, Inc.
47. Oregon Health & Science University
48. Oxford Performance Materials
51. Rainbow Biosciences
55. Roland DG Corporation
56. Roslin Cellab
58. Sciperio / nScrypt
60. Seattle Genetics
65. TeVido BioDevices
66. The Technology Partnership
67. Unique Technology
68. United Therapeutics
70. Vivos Dental
71. Wake Forest Institute for Regenerative Medicine
75. Z Corporation
77. Zurich University of Applied Sciences
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
Aug. 29, 2016 03:00 AM EDT Reads: 2,392
With so much going on in this space you could be forgiven for thinking you were always working with yesterday’s technologies. So much change, so quickly. What do you do if you have to build a solution from the ground up that is expected to live in the field for at least 5-10 years? This is the challenge we faced when we looked to refresh our existing 10-year-old custom hardware stack to measure the fullness of trash cans and compactors.
Aug. 29, 2016 02:15 AM EDT Reads: 1,816
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
Aug. 29, 2016 02:15 AM EDT Reads: 2,198
The emerging Internet of Everything creates tremendous new opportunities for customer engagement and business model innovation. However, enterprises must overcome a number of critical challenges to bring these new solutions to market. In his session at @ThingsExpo, Michael Martin, CTO/CIO at nfrastructure, outlined these key challenges and recommended approaches for overcoming them to achieve speed and agility in the design, development and implementation of Internet of Everything solutions wi...
Aug. 29, 2016 01:45 AM EDT Reads: 2,174
Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is expected in the amount of information being processed, managed, analyzed, and acted upon by enterprise IT. This amazing is not part of some distant future - it is happening today. One report shows a 650% increase in enterprise data by 2020. Other estimates are even higher....
Aug. 29, 2016 01:15 AM EDT Reads: 3,008
With over 720 million Internet users and 40–50% CAGR, the Chinese Cloud Computing market has been booming. When talking about cloud computing, what are the Chinese users of cloud thinking about? What is the most powerful force that can push them to make the buying decision? How to tap into them? In his session at 18th Cloud Expo, Yu Hao, CEO and co-founder of SpeedyCloud, answered these questions and discussed the results of SpeedyCloud’s survey.
Aug. 29, 2016 01:00 AM EDT Reads: 2,222
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
Aug. 29, 2016 12:00 AM EDT Reads: 1,889
Actian Corporation has announced the latest version of the Actian Vector in Hadoop (VectorH) database, generally available at the end of July. VectorH is based on the same query engine that powers Actian Vector, which recently doubled the TPC-H benchmark record for non-clustered systems at the 3000GB scale factor (see tpc.org/3323). The ability to easily ingest information from different data sources and rapidly develop queries to make better business decisions is becoming increasingly importan...
Aug. 28, 2016 11:15 PM EDT Reads: 2,150
The 19th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportuni...
Aug. 28, 2016 10:30 PM EDT Reads: 4,060
Qosmos has announced new milestones in the detection of encrypted traffic and in protocol signature coverage. Qosmos latest software can accurately classify traffic encrypted with SSL/TLS (e.g., Google, Facebook, WhatsApp), P2P traffic (e.g., BitTorrent, MuTorrent, Vuze), and Skype, while preserving the privacy of communication content. These new classification techniques mean that traffic optimization, policy enforcement, and user experience are largely unaffected by encryption. In respect wit...
Aug. 28, 2016 08:30 PM EDT Reads: 1,843
Deploying applications in hybrid cloud environments is hard work. Your team spends most of the time maintaining your infrastructure, configuring dev/test and production environments, and deploying applications across environments – which can be both time consuming and error prone. But what if you could automate provisioning and deployment to deliver error free environments faster? What could you do with your free time?
Aug. 28, 2016 08:15 PM EDT Reads: 1,957
SYS-CON Events announced today that Hitrons Solutions will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Hitrons Solutions Inc. is distributor in the North American market for unique products and services of small and medium-size businesses, including cloud services and solutions, SEO marketing platforms, and mobile applications.
Aug. 28, 2016 07:30 PM EDT Reads: 714
Smart Cities are here to stay, but for their promise to be delivered, the data they produce must not be put in new siloes. In his session at @ThingsExpo, Mathias Herberts, Co-founder and CTO of Cityzen Data, will deep dive into best practices that will ensure a successful smart city journey.
Aug. 28, 2016 06:30 PM EDT Reads: 1,635
SYS-CON Events announced today that 910Telecom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and ...
Aug. 28, 2016 06:00 PM EDT Reads: 1,948
SYS-CON Events announced today that eCube Systems, a leading provider of middleware modernization, integration, and management solutions, will exhibit at @DevOpsSummit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. eCube Systems offers a family of middleware evolution products and services that maximize return on technology investment by leveraging existing technical equity to meet evolving business needs. ...
Aug. 28, 2016 05:30 PM EDT Reads: 786